Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGA303
- Development stage
- Preclinical
- Lead developer
- BMG Pharma
- Administration
- Intradermal
01
Overview
SGA303 is a preclinical-stage injectable dermal filler developed by BMG Pharma for applications in aesthetic medicine. It is specifically designed for administration into the mid-dermis to provide structural support and volume restoration. As a medical device candidate in the aesthetic space, SGA303 aims to address cosmetic indications through mechanical augmentation of the skin's dermal layer.
- Other names
- SGA303 Filler Mid DermisSGA-303 Filler Mid DermisSGA 303 Filler Mid Dermis
Beyond the preview
Go deeper on SGA303.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGA303.